US2018009750A1PendingUtilityA1
5-methoxytryptophan and its derivatives and uses thereof
Est. expiryJan 13, 2035(~8.4 yrs left)· nominal 20-yr term from priority
A61P 29/00C07D 209/20A61K 31/405
31
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A 5-methoxytryptophan and its derivatives are disclosed, wherein the 5-methoxytryptophan and its derivatives are represented by the following formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are defined in the specification. In addition, the present invention also provides novel used of the 5-methoxytryptophan and its derivatives for treating inflammatory-related disease and cancers.
Claims
exact text as granted — not AI-modified1 . A method for treating an inflammatory-related disease, comprising administering to a subject in need thereof and effective amount of a compound of formula (I):
Wherein
R 1 is H, halogen atom, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 2 is C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 3 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 4 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C(O)R a , or C(O)OR a ; in which R a is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl;
R 5 is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and
n is 0-5.
2 . The method as claimed in claim 1 , wherein each R 1 and R 2 , independently, is H or C 1 -C 10 alkyl.
3 . The method as claimed in claim 2 , wherein R 1 is H, and R 2 is C 1 -C 3 alkyl.
4 . The method as claimed in claim 1 , wherein R 3 is H, C 1 -C 10 alkyl, and R 4 is H, C 1 -C 10 alkyl, C(O)R a , or C(O)OR a , in which R a is H, or C 1 -C 10 alkyl.
5 . The method as claimed in claim 4 , wherein R 3 is H, and R 4 is H or C(O)R a , in which R a is C 1 -C 3 alkyl.
6 . The method as claimed in claim 1 , wherein R 5 is H or C 1 -C 10 alkyl.
7 . The method as claimed in claim 6 , wherein R 5 is H or C 1 -C 3 alkyl.
8 . The method as claimed in claim 1 , wherein n is 1 or 2.
9 . The method as claimed in claim 1 , wherein the inflammatory-related disease is sepsis, Systemic Lupus Erythematosus (SLE), cardiovascular diseases, metabolic syndrome, cancer, septicemia and diverse inflammatory joint, gastrointestinal, or renal diseases.
10 . The method as claimed in claim 9 , wherein the inflammatory-related disease is sepsis, SLE or cancer.
11 . The method as claimed in claim 1 , wherein the compound is
12 . A method for treating a cancer, comprising administering to a subject in need thereof and effective amount of a compound of formula (I):
Wherein
R 1 is H, halogen atom, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 2 is alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 3 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 4 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C(O)R a , or C(O)OR a ; in which R a is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl;
R 5 is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and
n is 0-5.
13 . The method as claimed in claim 12 , wherein each R 1 and R 2 , independently, is H or C 1 -C 10 alkyl.
14 . The method as claimed in claim 13 , wherein R 1 is H, and R 2 is C 1 -C 3 alkyl.
15 . The method as claimed in claim 12 , wherein R 3 is H, C 1 -C 10 alkyl, and R 4 is H, C 1 -C 10 alkyl, C(O)R a , or C(O)OR a , in which R a is H, or C 1 -C 10 alkyl.
16 . The method as claimed in claim 15 , wherein R 3 is H, and R 4 is H or C(O)R a , in which R a is C 1 -C 3 alkyl.
17 . The method as claimed in claim 12 , wherein R 5 is H or C 1 -C 10 alkyl.
18 . The method as claimed in claim 17 , wherein R 5 is H or C 1 -C 3 alkyl.
19 . The method as claimed in claim 12 , wherein n is 1 or 2.
20 . The method as claimed in claim 12 , wherein the cancer is a lung cancer, or a breast cancer.
21 . The method as claimed in claim 1 , wherein the compound is
22 . A compound of formula (I):
Wherein
R 1 is H, halogen atom, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 2 is C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 3 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 4 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C(O)R a , or C(O)OR a ; in which R a is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl;
R 5 is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and
n is 0-5,
with the proviso that R 1 , R 3 , R 4 and R 5 are not H when R 2 is C 1 -C 10 alkyl.
23 . The compound as claimed in claim 22 , wherein each R 1 and R 2 , independently, is H or C 1 -C 10 alkyl.
24 . The compound as claimed in claim 23 , wherein R 1 is H, and R 2 is C 1 -C 3 alkyl.
25 . The compound as claimed in claim 22 , wherein R 3 is H, C 1 -C 10 alkyl, and R 4 is H, C 1 -C 10 alkyl, C(O)R a , or C(O)OR a , in which R a is H, or C 1 -C 10 alkyl.
26 . The compound as claimed in claim 25 , wherein R 3 is H, and R 4 is H or C(O)R a , in which R a is C 1 -C 3 alkyl.
27 . The compound as claimed in claim 22 , wherein R 5 is H or C 1 -C 10 alkyl.
28 . The compound as claimed in claim 27 , wherein R 5 is H or C 1 -C 3 alkyl.
29 . The compound as claimed in claim 22 , wherein n is 1 or 2.
30 . The compound as claimed in claim 22 , which is
31 . A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of formula (I):
wherein
R 1 is H, halogen atom, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 2 is C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 3 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, or C 3 -C 20 cycloalkenyl;
R 4 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C(O)R a , or C(O)OR a ; in which R a is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl;
R 5 is H, C 1 -C 10 alkyl, C 3 -C 20 cycloalkyl, C 3 -C 20 heterocycloalkyl, aryl, or heteroaryl; and
n is 0-5,
with the proviso that R 1 , R 3 , R 4 and R 5 are not H when R 2 is C 1 -C 10 alkyl.Join the waitlist — get patent alerts
Track US2018009750A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.